A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

MindPortal Raises $5 Million

MindPortal creators of the next personal computer that is a wearable non-invasive brain-computer interface, announced today it completed a $5 Million seed round of financing.

Learn Capital led the round, with additional investment from Kleiner Perkins; Dan Siroker, Founder & CEO of Scribe AI; Matt Bellamy, rockstar and frontman of Muse; James Park, Co-Founder & CEO of Fitbit; Julie Zhou, Co-Founder of Sundial and former Vice President of Product Design for Facebook; Scrum Ventures; and additional angels from frontier tech, hardware and product design. Previous pre-seed investors included 7pc and Y Combinator. The new funding will be used to hire additional neuroscientists, product engineers and machine learning experts.

Presently, MindPortal’s patent pending wearable device can record human brain activity in real time, without surgery, with 10-100x more precision than EEG technology. The platform brain computer being developed will act as a bi-directional portal; connecting the mind to immersive, creative and playful experiences and also as a gateway into the mind. When wearing MindPortal’s device, people will be able to create and share new experiences e.g. in VR/AR, just by using their thoughts, and channel experiences into their mind.

“We’re animated by a vision of the future where every human on the planet has a greater opportunity to fully develop their talents and minds,” said Rob Hutter, Founder & Managing Partner of Learn Capital. “MindPortal is pursuing what some would call the holy grail – namely, a portable and non-invasive platform that samples brain activity at high spatial and temporal resolution, a technical feat that could unleash the potential for a dramatic improvement in productivity across work, play and life.”

“All technology has been generated from the ingenuity of the human mind, but for the first time in the history of our species, we are turning that ingenuity towards creating technology that enhances the human mind itself,” Ekram Alam, Co-founder & CEO of MindPortal.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy